Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Although immune mechanisms can suppress tumour growth, tumours establish potent, overlapping mechanisms that mediate immune evasion. Emerging evidence suggests a link between angiogenesis and the tolerance of tumours to immune mechanisms. Hypoxia, a condition that is known to drive angiogenesis in tumours, results in the release of damage-associated pattern molecules, which can trigger the rejection of tumours by the immune system. Thus, the counter-activation of tolerance mechanisms at the site of tumour hypoxia would be a crucial condition for maintaining the immunological escape of tumours. However, a direct link between tumour hypoxia and tolerance through the recruitment of regulatory cells has not been established. We proposed that tumour hypoxia induces the expression of chemotactic factors that promote tolerance. Here we show that tumour hypoxia promotes the recruitment of regulatory T (T(reg)) cells through induction of expression of the chemokine CC-chemokine ligand 28 (CCL28), which, in turn, promotes tumour tolerance and angiogenesis. Thus, peripheral immune tolerance and angiogenesis programs are closely connected and cooperate to sustain tumour growth.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hypoxia, through HIF-1α, drives the conversion of MDSCs into antigen-nonspecific suppressors of T cell function and promotes the differentiation of MDSCs into immune-suppressive TAMs, further potentiating the immune-suppressive network [80].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [80]
In the citing paper
“For example, both HIF-1α and HIF-2α induce the production of CCL28, which promotes the recruitment of MDSCs into hepatocellular tumors, whereas HIF-1α induces production of CCL26 that enhances recruitment of Tregs into ovarian tumors (Table 1) [69, 70].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [69]
In the citing paper
“For example, both HIF-1α and HIF-2α induce the production of CCL28, which promotes the recruitment of MDSCs into hepatocellular tumors, whereas HIF-1α induces production of CCL26 that enhances recruitment of Tregs into ovarian tumors (Table 1) [69, 70].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [69]
In the citing paper
“In addition to increasing drug resistance, a high SS could influence tumor cells' gene expression, comprise immune cells ability to kill cancerous cells or even turn macrophages to tumorfriendly cells, thereby enhancing the metastatic potential of cancer cells [180-184].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [181]
In the citing paper
“tumours secrete soluble factors, such as C-C-motif chemokine ligand 2 (CCL2), CCL28, C-X-C-motif chemokine ligand 8 (CXCL8), CXCL12, ANG2, VEGF, PlGF, and adenosine, all of which promote the recruitment of immunosuppressive cells7,17–20 (FIG. 2)”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [17]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Self-citationSummaries of Affymetrix GeneChip probe level data
Irizarry, R. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng015 · Cited by 4,887
Camp, R. L., Dolled-Filhart, M., & Rimm, D. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0713 · Cited by 3,744
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Self-citationImmunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
Bild, A. H., Yao, G., Chang, J. T., Wang, Q., Potti, A., Chasse, D., Joshi, M.-B., Harpole, D., Lancaster, J. M., Berchuck, A., et al. (2006) · Nature · doi:10.1038/nature04296 · Cited by 2,032
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., Johnson, D. S., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,467
Adaptive immunity maintains occult cancer in an equilibrium state
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,436
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314
Cited by
Items 601–700 of 1,002
Qiao, M., Zhou, F., Hou, L., Li, X., Zhao, C., Jiang, T., Gao, G., Su, C., Wu, C., Ren, S., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-1471 · Cited by 42
“Therefore, a hypoxia tumor condition in liver TME with high VEGF expression could contribute to the induction of immunosuppressive immune cells to form an immunosuppressive TME (24,25).”
Zhou, L., He, X., Cai, P., Li, T., Peng, R., Dang, J., Li, Y., Li, H., Huang, F., Shi, G., et al. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00623-2 · Cited by 39
Kurebayashi, Y., Olkowski, C. P., Lane, K. C., Vasalatiy, O. V., Xu, B., Okada, R., Furusawa, A., Choyke, P. L., Kobayashi, H., & Sato, N. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2673 · Cited by 40
“S10), induction of VEGF expression (Supplementary Fig.”
BackgroundImplications of regulatory T cells in anti-cancer immunity: from pathogenesis to therapeutics
Dwivedi, M., Tiwari, S., Kemp, E. H., & Begum, R. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e10450 · Cited by 42
Physiology of chemokines in the cancer microenvironment
Drouillard, D., Craig, B. T., & Dwinell, M. B. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00151.2022 · Cited by 41
Oxygen-dependent regulation of immune checkpoint mechanisms
Ohta, A. (2018) · International Immunology · doi:10.1093/intimm/dxy038 · Cited by 39
Zhang, C., Bingxiang, T., Hu, J., Fang, X., Bian, H., Han, J., Hou, C., & Fang, S. (2021) · Bioengineered · doi:10.1080/21655979.2021.1987820 · Cited by 39
“Hypoxia not only tightly regulates the production of specific chemokines, it also controls their action by regulating their receptors [29,30].”
BackgroundApplication of photodynamic activation of prodrugs combined with phototherapy in tumor treatment
Du, Y., Zhao, J., Li, S., & Yuan, H. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02404-9 · Cited by 46
Arens, R. (2012) · Advances in immunology · doi:10.1016/b978-0-12-396548-6.00009-3 · Cited by 38
Modulating T regulatory cells in cancer: how close are we?
Banerjee, A., Vasanthakumar, A., & Grigoriadis, G. (2013) · Immunology and Cell Biology · doi:10.1038/icb.2013.12 · Cited by 44
VEGF blockade enhances the antitumor effect of BRAFV600E inhibition
Comunanza, V., Corà, D., Orso, F., Consonni, F. M., Middonti, E., Nicolantonio, F. D., Buzdin, A. A., Sica, A., Médico, E., Sangiolo, D., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505774 · Cited by 40
“Hypoxia also recruits regulatory T-cell (Treg) effectors for tumor tolerance (Facciabene et al, 2011), and up-regulates the expression of programmed death (PD-1) ligand 1 (Noman et al, 2014), which favors the suppressive activity of MDSC (Greenwald et al, 2005).”
BackgroundYang, J., Wang, W., Xia, H.-F., Yu, Z., Li, H., Ren, J., Chen, G., Wang, B., Jia, J., Zhang, W., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32221 · Cited by 37
Ping-Pong—Tumor and Host in Pancreatic Cancer Progression
Mu, W., Wang, Z., & Zöller, M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01359 · Cited by 38
“PaCa secrete elevated levels of CCR5 ligands/CCL28, which increases Treg chemotaxis (733).”
BackgroundLee, T. W., Lai, A., Harms, J. K., Singleton, D. C., Dickson, B. D., Macann, A., Hay, M. P., & Jamieson, S. M. F. (2020) · Cancers · doi:10.3390/cancers12123743 · Cited by 40
Zhang, Q., Shao, B., Tong, Z., Ouyang, Q., Wang, Y., Xu, G., Li, S., & Li, H. (2022) · BMC Medicine · doi:10.1186/s12916-022-02527-6 · Cited by 41
Interaction between regulatory T cells and cancer stem cells
Yu, X., Li, H. Z., & Ren, X. (2012) · International Journal of Cancer · doi:10.1002/ijc.27634 · Cited by 39
Krech, T., Scheuerer, E., Geffers, R., Kreipe, H. H., Lehmann, U., & Christgen, M. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.09.038 · Cited by 37
Murthy, A., Gerber, S. A., Koch, C. J., & Lord, E. M. (2019) · ImmunoHorizons · doi:10.4049/immunohorizons.1900017 · Cited by 36
“These included the chemokines ccl28 (involved with regulatory T cell migration) (36, 37) and cxc3cl1, which increases tumor cell migration and metastasis by enhancing epithelial-to-mesenchymal transition-like phenotype (38).”
The antitumor mechanisms of aerobic exercise: A review of recent preclinical studies
Jia, N., Zhou, Y., Dong, X., & Ding, M. (2021) · Cancer Medicine · doi:10.1002/cam4.4169 · Cited by 40
Regulatory T Cells, Leptin and Angiogenesis
Pucino, V., Rosa, V. D., Procaccini, C., & Matarese, G. (2013) · Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy · doi:10.1159/000353557 · Cited by 44
Roy, I., Boyle, K. A., Vonderhaar, E. P., Zimmerman, N. P., Gorse, E., Mackinnon, A. C., Hwang, R. F., Franco‐Barraza, J., Cukierman, E., Tsai, S., et al. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2016.146 · Cited by 38
“Previous work examining the functional role of the CCL28 chemokine ligand, and its receptor CCR10, in cancer have primarily focused on its impact on T-cell mediated disease (37, 42).”
BackgroundResultManini, I., Caponnetto, F., Dalla, E., Ius, T., Pepa, G. M. D., Pegolo, E., Bartolini, A., Rocca, G. L., Menna, G., Loreto, C. D., et al. (2020) · Cancers · doi:10.3390/cancers12102960 · Cited by 37
“Here, Treg cells promote tumor tolerance and are a source of VEGF, thus contributing to angiogenesis [84].”
BackgroundMetabolic profiles of regulatory T cells in the tumour microenvironment
Rao, D., Verburg, F., Renner, K., Peeper, D. S., Lacroix, R., & Blank, C. U. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02881-z · Cited by 221
Clinical efficacy and safety of angiogenesis inhibitors: sex differences and current challenges
Cignarella, A., Fadini, G. P., Bolego, C., Trevisi, L., Boscaro, C., Sanga, V., Seccia, T. M., Rosato, A., Rossi, G. P., & Barton, M. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab096 · Cited by 39
Interactions Between Anti-Angiogenic Therapy and Immunotherapy in Glioblastoma
Jain, S., Chalif, E. J., & Aghi, M. K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.812916 · Cited by 38
“Regulatory T cells have been implicated as proangiogenic forces, and their depletion in ovarian cancer resulted in robust reduction of the VEGF as measured in tumor microenvironment (123).”
BackgroundTissue Resident Foxp3+ Regulatory T Cells: Sentinels and Saboteurs in Health and Disease
Lee, J., Kim, D., & Min, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.865593 · Cited by 40
Nanomaterial-Based Drug Delivery Systems: A New Weapon for Cancer Immunotherapy
Jiang, Z., Zhang, W., Zhang, J., Liu, T., Xing, J., Zhang, H., & Tang, D. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s376216 · Cited by 42
Han, J., Jeong, W., Gu, M. J., Yoo, I., Yun, C., Kim, J., & Ka, H. (2018) · Biology of Reproduction · doi:10.1093/biolre/ioy147 · Cited by 36
The role of HIF in angiogenesis, lymphangiogenesis, and tumor microenvironment in urological cancers
Shen, L., Chai, Y., Zheng, X., & Xu, X. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08931-2 · Cited by 37
“The hypoxic TME also recruits regulatory T cells (Tregs) via the secretion of CC-chemokine ligand 28 [ 67].”
BackgroundTakei, S., Tanaka, Y., Lin, Y.-T., Koyama, S., Fukuoka, S., Hara, H., Nakamura, Y., Kuboki, Y., Kotani, D., Kojima, T., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008210 · Cited by 38
Treg-Mediated Immune Tolerance and the Risk of Solid Cancers: Findings From EPIC-Heidelberg
Barth, S. D., Schulze, J., Kuhn, T. E., Raschke, E. E., Hüsing, A., Johnson, T., Kaaks, R., & Olek, S. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv224 · Cited by 35
Transcriptional Regulation of Chemokine Expression in Ovarian Cancer
Singha, B., Gatla, H. R., & Vancurova, I. (2015) · Biomolecules · doi:10.3390/biom5010223 · Cited by 35
Yamanoi, K., Arai, E., Tian, Y., Takahashi, Y., Miyata, S., Sasaki, H., Chiwaki, F., Ichikawa, H., Sakamoto, H., Kushima, R., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv013 · Cited by 35
“Tumor hypoxia promotes the recruitment of regulatory T cells through induction of CCL28 expression, resulting in immune tolerance and tumor angiogenesis (47).”
BackgroundNoel, G. L., Fontsa, M. L., & Willard-Gallo, K. E. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.03.003 · Cited by 35
Sahara, K., Tsilimigras, D. I., Toyoda, J., Miyake, K., Ethun, C. G., Maithel, S. K., Abbott, D. E., Poultsides, G. A., Hatzaras, I. S., Fields, R. C., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-09811-4 · Cited by 39
Regulation of in vivo delivery of nanomedicines by herbal medicines
Guan, J., Chen, W., Yang, M., Wu, E., Qian, J., & Zhan, C. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.04.015 · Cited by 37
Atomic Force Microscopy Probing of Cancer Cells and Tumor Microenvironment Components
Stylianou, A., & Stylianopoulos, T. (2015) · BioNanoScience · doi:10.1007/s12668-015-0187-4 · Cited by 39
Zhang, B., Wei, C., Chang, K., Yu, J., Zhou, W., Yang, H., Shao, J., Yu, J., Li, M., & Xie, F. (2017) · Oncology Letters · doi:10.3892/ol.2017.7121 · Cited by 35
“In the majority of types of solid tumor, EOS tissue infiltration is located in the tumor necrosis area (21).”
Yu, P., Wang, Y., Yuan, D., Sun, Y., Qin, S., & Li, T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1276694 · Cited by 37
Zhang, T., Lv, Q., & Jin, W. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189137 · Cited by 44
Zhou, Y., Singh, A. K., Hoyt, R. F., Wang, S., Yu, Z., Hunt, T. J., Kindzelski, B. A., Corcoran, P. C., Mohiuddin, M. M., & Horvath, K. A. (2014) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2014.06.029 · Cited by 36
“Studies have shown that CD4+CD25hiFoxP3+ T regulatory (Treg) cells have the potential to suppress inflammation, promote angiogenesis, induce tolerance and provide a favorable environment for cellular engraftment (11,12).”
WANG, Y., SUN, J., ZHENG, R., Shao, Q., Gao, W., SONG, B., CHEN, X., & Qu, X. (2016) · Neoplasma · doi:10.4149/neo_2016_517 · Cited by 38
Inflammation and immunity in ovarian cancer
Salas‐Benito, D., Vercher, E., Conde, E., Glez‐Vaz, J., Tamayo, I., & Hervás‐Stubbs, S. (2020) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2019.12.002 · Cited by 38
“[83] Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang L-P, et al.”
BackgroundNishina, S., & Hino, K. (2022) · Cancers · doi:10.3390/cancers14020454 · Cited by 34
Regulatory T cells and Pulmonary Hypertension
Tamosiuniene, R., & Nicolls, M. (2011) · Trends in cardiovascular medicine · doi:10.1016/j.tcm.2012.05.004 · Cited by 38
Ekanger, L. A., Polin, L., Shen, Y., Haacke, E. M., & Allen, M. J. (2016) · Contrast Media & Molecular Imaging · doi:10.1002/cmmi.1692 · Cited by 36
Learning from the nexus of autoimmunity and cancer
Mangani, D., Yang, D., & Anderson, A. C. (2023) · Immunity · doi:10.1016/j.immuni.2023.01.022 · Cited by 33
Why Treg should be the focus of cancer immunotherapy: The latest thought
Liu, Z., Zhou, J., Shi-hui, W., Chen, Z., Wu, S., Chen, L., Zhu, X. M., & Li, Z. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115142 · Cited by 36
The role of VEGF in Cancer angiogenesis and tumorigenesis: Insights for anti-VEGF therapy
Shi, Z., Kuai, M., Li, B., Akowuah, C. F., Wang, Z., Pan, Y., Tang, M., Yang, X., & Lü, P. (2025) · Cytokine · doi:10.1016/j.cyto.2025.156908 · Cited by 37
Zou, H., Lv, G.-Q., Dai, L.-H., Zhan, X.-H., Jiao, J.-W., Liao, L., Zhou, T., Li, C., Wu, B., Xu, L., et al. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.04.003 · Cited by 34
Vascular abnormalities and development of hypoxia in microscopic melanoma xenografts
Gaustad, J., Simonsen, T. G., Andersen, L. M. K., & Rofstad, E. K. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1347-9 · Cited by 37
Gastric Cancer in the Era of Immune Checkpoint Blockade
Figueroa-Protti, L., Soto-Molinari, R., Calderón-Osorno, M., Mora, J., & Alpízar‐Alpízar, W. (2019) · Journal of Oncology · doi:10.1155/2019/1079710 · Cited by 34
Effects of Hypoxia in Intestinal Tumors on Immune Cell Behavior in the Tumor Microenvironment
Zhang, L., Wang, S., Wang, Y., Zhao, W., Zhang, Y., Zhang, N., & Xu, H. W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.645320 · Cited by 37
“Hypoxia is a feature of tumor physiology specifically that of mechanisms associated with the acquisition of some malignant attributes, such as metastasis, invasion (7–9), and drug resistance (10).”
BackgroundSelf-citationCao, R., Ma, B., Wang, G., Xiong, Y., Tian, Y., & Yuan, L. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.06.011 · Cited by 39
Combined nano cancer immunotherapy based on immune status in a tumor microenvironment
Nakamura, T., Kawakami, K., Nomura, M., Sato, Y., Hyodo, M., Hatakeyama, H., Hayakawa, Y., & Harashima, H. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.026 · Cited by 34
Bonet‐Aleta, J., Calzada-Funes, J., & Hueso, J. L. (2022) · Applied Materials Today · doi:10.1016/j.apmt.2022.101628 · Cited by 41
Terefe, E. M., Opulencia, M. J. C., Rakhshani, A., Ansari, M. J., Sergeevna, S. E., Awadh, S. A., Polatova, D. S., Abdulkadhim, A. H., Mustafa, Y. F., Kzar, H. H., et al. (2022) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2022.28 · Cited by 33
Zhang, S., Yao, L., Wang, W., Xu, J., Xu, H., Jin, W., Gao, H.-L., Wu, C., Qi, Z., Li, H., et al. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6727-8 · Cited by 38
Noman, M. Z., Janji, B., Berchem, G., & Chouaïb, S. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.10.026 · Cited by 36
Brenner, A. K., Reikvam, H., & Bruserud, Ø. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00205 · Cited by 33
“The bone marrow microenvironment is hypoxic, and studies in experimental models strongly suggest that CCL28 is important for cell trafficking and angiogenesis in hypoxic microenvironments associated with carcinogenesis (31).”
BackgroundRIG-I Resists Hypoxia-Induced Immunosuppression and Dedifferentiation
Engel, C., Brügmann, G., Lambing, S., Mühlenbeck, L. H., Marx, S., Hagen, C., Horváth, D., Goldeck, M., Ludwig, J., Herzner, A., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0129-t · Cited by 35
Wen, Q.-X., Han, T., Wang, Z., & Jiang, S. (2020) · Oncology Letters · doi:10.3892/ol.2020.11369 · Cited by 44
“Previous studies have revealed that tumor hypoxia alters the composition and activity of tumor-associated immune cells, and that numerous immune cells with immunosuppressive activities are recruited to tumor tissues to form the immunosuppressive microenvironment (18,50,51).”
BackgroundZaitsu, J., Yamashita, Y., Ishikawa, A., Saito, A., Kagimoto, A., Mimura, T., Hirakawa, T., Mito, M., Fukuhara, K., SENOO, T., et al. (2021) · Anticancer Research · doi:10.21873/anticanres.15158 · Cited by 34
Liu, Z., Tang, Q., Qi, T., Othmane, B., Yang, Z., Chen, J., Hu, J., & Zu, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.725223 · Cited by 38
“Hypoxia upregulates the infiltration levels of Treg cells by increasing the expression of the FOXP3 transcription factor, TGF-b, and CCL28, which may inhibit the anti-cancer immune responses (41, 42).”
BackgroundBrain Immune Interactions—Novel Emerging Options to Treat Acute Ischemic Brain Injury
Muhammad, S., Chaudhry, S. R., Kahlert, U. D., Niemela, M. R., & Hänggi, D. (2021) · Cells · doi:10.3390/cells10092429 · Cited by 38
“On one hand, the polarization of T helper cells towards Th1 type CD4+ cells inhibit angiogenesis through the release of IFN-γ [119] and on the other hand, Th2 type CD4+ cells and regulatory T cells promote angiogenesis via releasing VEGF and TGF-β [120,121].”
BackgroundNie, Y., Fan, H., Li, J., Lei, X., Zhang, T., Wang, Y., Mao, Z., Tao, K., & Song, W. (2022) · The FASEB Journal · doi:10.1096/fj.202200269rr · Cited by 33
Pankowska, K. A., Będkowska, G. E., Chociej-Stypułkowska, J., Rusak, M., Dąbrowska, M., & Osada, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119279 · Cited by 36
“Notably, hypoxia-induced CCL28 overexpression enhances Treg cell migration to the OC TME via a mechanism involving CCR10, which also leads to IL-10 secretion [88].”
BackgroundAhuja, S., & Zaheer, S. (2023) · Cell Biology International · doi:10.1002/cbin.12097 · Cited by 37
“It also leads to a reduction of efficacy of systemic administration of chemo ‐ radio ‐ immuno ‐ and nanotherapy (Facciabene et al., 2011; Jain et al., 2014).”
BackgroundGu, X., Jiang, Z., & Fang, W. (2011) · Journal of International Medical Research · doi:10.1177/147323001103900516 · Cited by 32
Sabnis, S., Sabnis, N. A., Raut, S., & Lacko, A. G. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s122036 · Cited by 35
Basal, L. A., & Allen, M. J. (2018) · Frontiers in Chemistry · doi:10.3389/fchem.2018.00065 · Cited by 32
“Because of these tunable properties, divalent europium complexes have potential use as molecular-imaging probes that sense O2, which is important because O2 imbalances are often correlated with disease (Shweiki et al., 1992; Barnham et al., 2004; Mattson, 2004; Lin and Beal, 2006; Park et al., 2008; Facciabene et al.,…”
BackgroundDavern, M., Donlon, N. E., O’Connell, F., Gaughan, C., O’Donovan, C., McGrath, J., Sheppard, A. D., Hayes, C., King, R., Temperley, H. C., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04440-0 · Cited by 35
Park, Y., & Jeong, E. M. (2024) · International Journal of Stem Cells · doi:10.15283/ijsc24060 · Cited by 33
“In the hypoxic TME, Tregs produce a significant amount of VEGF, which mediates angiogenesis and enhances the expansion of CSCs (69).”
BackgroundAngeli, S., Neophytou, C., Kalli, M., Stylianopoulos, T., & Mpekris, F. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1564626 · Cited by 41
Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance
Bonavida, B., & Chouaïb, S. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw615 · Cited by 33
“The polarization of macrophages to type II (M2), which secrete chemokines to recruit T-regs, also contributes to immune-suppression [53].”
BackgroundVascular Co-Option and Other Alternative Modalities of Growth of Tumor Vasculature in Glioblastoma
Ribatti, D., & Pezzella, F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.874554 · Cited by 37
“In GBM, tumor-associated macrophages (TAMs) crosstalk with Treg cells to release pro-angiogenic and immune-suppressive VEGF (28).”
BackgroundWang, F., Yang, M., Luo, W., & Zhou, Q. (2022) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2022.10.002 · Cited by 42
“30 , 31 CCR10 + Tregs can be recruited by tumor cells through the production of CCL28.”
BackgroundIn Vitro Modeling of Tumor–Immune System Interaction
Mengus, C., Muraro, M. G., Mele, V., Amicarella, F., Manfredonia, C., Foglietta, F., Muenst, S. E., Soysal, S. D., Iezzi, G., & Spagnoli, G. C. (2017) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.7b00077 · Cited by 34
Mechanisms regulating immune surveillance of cellular stress in cancer
Seelige, R., Searles, S. C., & Bui, J. D. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2597-7 · Cited by 38
“Moreover, it was shown in an ovarian cancer model that tumor cells can secrete the TReg-recruiting chemokine CCL28 under hypoxic conditions [54].”
BackgroundImmunotherapy in colorectal cancer
Agarwal, P., Le, D. T., & Boland, P. M. (2021) · Advances in cancer research · doi:10.1016/bs.acr.2021.03.002 · Cited by 35
Necrosis in the Tumor Microenvironment and Its Role in Cancer Recurrence
Karsch-Bluman, A., & Benny, O. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-35727-6_6 · Cited by 37
Li, X., Shi, H. R., Zhang, W., Bai, C., He, M., Ta, N., Huang, H., Ning, Y., Chen, F., Qin, H., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.690115 · Cited by 37
CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment
Lecoq, I., Kopp, K., Chapellier, M., Mantas, P., Martinenaite, E., Perez-Penco, M., Olsen, L. R., Zocca, M.-B., Pedersen, A. W., & Andersen, M. H. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2115655 · Cited by 32
Celada, L., Cubiella, T., San‐Juan‐Guardado, J., Gutiérrez, G., Beiguela, B., Rodríguez, R. Q., Poch, M., Astudillo, A., Grijalba, A., Sobrino, P. S., et al. (2022) · The Journal of Pathology · doi:10.1002/path.6026 · Cited by 30
“One of the driving forces behind immunosuppression in cancer is mediated by HIF1α, which transcriptionally activates genes that block the infiltration and activity of CTLwhile stimulating the infiltration and activity of regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages [24,25].”
BackgroundPark, C., Jeong, D. Y., Choi, Y., Oh, Y. J., Kim, J., Ryu, J., Paeng, K., Lee, S., Ock, C., & Lee, H. Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1038089 · Cited by 32
“Hypoxia, in consequence of tumor outgrowth and insufficient vascularization, also induces regulatory T cell recruitment to promote angiogenesis and inhibit cytotoxic T cell activity (25, 26).”
BackgroundImmune checkpoint inhibitors in ovarian cancer: where do we go from here?
Yoon, W.-H., DeFazio, A., & Kasherman, L. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.13 · Cited by 32
Regulatory T‐cells promote hepatitis B virus infection and hepatocellular carcinoma progression
Li, W., Han, J., & Wu, H. M. (2016) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2016.09.001 · Cited by 37
“Apart from CCL22, tumor hypoxia can promote the recruitment of Tregs by upregulating CCL28.”
BackgroundInfluentialTownsend, K. N., Spowart, J. E., Huwait, H., Eshragh, S., West, N. R., Elrick, M. A., Kalloger, S. E., Anglesio, M., Watson, P. H., Huntsman, D. G., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082406 · Cited by 29
“using an epithelial murine ovarian cancer model showed that hypoxic tumors recruit FoxP3 expressing T reg cells to the tumor and these cells suppress antitumor immune cell subsets [15].”
Chemokine CCL17 induced by hypoxia promotes the proliferation of cervical cancer cell.
Liu, L., Xie, F., Chang, K., Shang, W.-Q., Meng, Y., Yu, J., Li, H., Sun, Q., Yuan, M., Jin, L., et al. (2015) · Europe PMC (PubMed Central) · Cited by 29
Minireview: Regulatory T Cells and Ovarian Cancer
Singh, M., Loftus, T., Webb, E., & Benencia, F. (2016) · Immunological Investigations · doi:10.1080/08820139.2016.1186689 · Cited by 29
“In a mouse model of ovarian cancer, blocking CCR10 decreased Treg infiltration to tumors and provided therapeutic benefits (Facciabene et al., 2011).”
InfluentialWang, M., He, H., Liu, D., Ma, M., & Zhang, Y. (2022) · Biomolecules · doi:10.3390/biom12091277 · Cited by 29
“It has been reported that low levels of intracellular ROS [54] and appropriate oxygen concentration [55] in the HUVEC cells are essential for anagenesis.”
BackgroundChen, Z., Guo, M., Li, Y.-Y., Yan, K., Li, L., Shen, F., Guan, H., Liu, Q., Xu, B., & Lian, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.894919 · Cited by 34
Neo-vascularization-based therapeutic perspectives in advanced ovarian cancer
Bhardwaj, V., Zhang, X., Pandey, V., & Garg, M. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188888 · Cited by 31
Positron emission tomography imaging sheds new light on hypoxia and antitumor therapies
Fang, H., Wang, X., Lan, X., & Jiang, D. (2023) · Interdisciplinary medicine · doi:10.1002/inmd.20230002 · Cited by 33
The role of tumor metabolism in modulating T-Cell activity and in optimizing immunotherapy
Ganjoo, S., Gupta, P., Corbali, H. I., Nanez, S., Riad, T. S., Duong, L. K., Barsoumian, H. B., Masrorpour, F., Jiang, H., Welsh, J. W., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1172931 · Cited by 35
“Hypoxia can also mediate immunosuppression by driving the recruitment of Tregs via CCchemokine ligand 28 (CCL28) signaling, which promotes tolerance and angiogenesis (67).”
BackgroundTargeting tumor vasculature: expanding the potential of DNA cancer vaccines
Ugel, S., Facciponte, J. G., Sanctis, F. D., & Facciabene, A. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1747-8 · Cited by 29
“Moreover, Treg are able to directly promote angiogenesis in ovarian cancer by production of CCL28 that increases VEGF levels in the tumor microenvironment [62].”
BackgroundSelf-citationMempel, T. R., & Marangoni, F. (2019) · Immunological Reviews · doi:10.1111/imr.12761 · Cited by 30
Antiangiogenic therapy and immune checkpoint blockade go hand in hand
Campesato, L. F., & Merghoub, T. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.10.12 · Cited by 29
“This l ist includes tumor-associated macrophages, myeloid-derived suppressor cells, TIE2+ monocytes, immature DCs, and T-reg cells which have been shown to have this dual capacity (3,14-16).”
BackgroundMa, J., Xu, C., Chen, Y., Tao, N., & Qin, Z. (2022) · Cancers · doi:10.3390/cancers14102406 · Cited by 31
“Compared to MDSCs [23], TAMs [24], Tregs [25], Bregs [26] and TANs [27], which are myeloid-derived immune negative regulatory cells, CAFs are the residual cells in the tumor microenvironment that create a “niche” for tumor cells and participate in the formation of the tumor microenvironment [28].”
BackgroundShafqat, A., Omer, M. H., Ahmed, E. N., Mushtaq, A. H., Ijaz, E., Ahmed, Z., AlKattan, K. M., & Yaqinuddin, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1200941 · Cited by 36
Metadata
- Authors
- Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., & Coukos, G.
- Affiliations
- University of Pennsylvania (US)
- University of British Columbia (CA)
- Corresponding author
- Coukos, George
- ORCID
- Venue
- Nature
- Published
- 2011-07
- Volume
- 475
- Issue
- 7355
- Pages
- 226-230
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2142644858
- Cited by
- 1,376
- References
- 38
- Citations by year
- 2026: 54 · 2025: 90 · 2024: 112 · 2023: 113 · 2022: 151 · 2021: 152 · 2020: 119 · 2019: 105 · 2018: 77 · 2017: 85 · 2016: 74 · 2015: 55 · 2014: 55 · 2013: 69 · 2012: 50
- FWCI
- 26.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (R01CA116779, P01 CA 83638)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- tumor hypoxia, regulatory T cells, CCL28, chemokine recruitment, tumor angiogenesis, VEGF-A, tumor immune evasion, tumor growth, chemokines
- MeSH terms
- Animals, Female, Humans, Immune Tolerance, Mice, Inbred C57BL, Neovascularization, Pathologic, Ovarian Neoplasms, Cell Hypoxia, Gene Expression Regulation, Neoplastic, Culture Media, Conditioned, Disease Progression, Chemokines, CC, Vascular Endothelial Growth Factor A, Cell Line, Tumor, T-Lymphocytes, Regulatory, Mice, Receptors, CCR10
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.